Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1

Frontiers in Immunology

Bargavi Thyagarajan¹  R. Keith Reeves²  Stephen J. Kent³  Guido Ferrari⁴  Julie Overbaugh⁵  George K. Lewis⁶  Christiane Moog⁷  Margaret E. Ackerman⁸  Marjorie Robert-Guroff⁹  Gabriella Scarlatti^1,10 

[1] 0Global HIV Vaccine Enterprise, New York, NY, United States;Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, United States;Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia;Department of Surgery and Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States;Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, United States;Division of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States;INSERM U1109, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France;Thayer School of Engineering, Dartmouth College, Hanover, NH, United States;Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institues of Health, Bethesda, MD, United States;Viral Evolution and Transmission Unit, Department of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy;

关键词: HIV—human immunodeficiency virus;    antibodies;    effector function;    ADCC—antibody dependent cellular cytotoxicity;    Fc receptor;   

DOI  :  10.3389/fimmu.2019.01025

来源: DOAJ

【 摘 要 】

It is now well-accepted that Fc-mediated effector functions, including antibody-dependent cellular cytotoxicity (ADCC), can contribute to vaccine-elicited protection as well as post-infection control of HIV viremia. This picture was derived using a wide array of ADCC assays, no two of which are strictly comparable, and none of which is qualified at the clinical laboratory level. An earlier comparative study of assay protocols showed that while data from different ADCC assay formats were often correlated, they remained distinct in terms of target cells and the epitopes and antigen(s) available for recognition by antibodies, the effector cells, and the readout of cytotoxicity. This initial study warrants expanded analyses of the relationships among all current assay formats to determine where they detect overlapping activities and where they do not. Here we summarize knowns and unknowns of assaying ADCC against HIV-1.

【 授权许可】

Unknown